Vyas 1980.

Methods	Allocation: randomised ‐ no further details. Blinding: double ‐ identical capsules. Duration: 6 months ‐ preceded by 15 day antipsychotic free period. Setting: single centre.
Participants	Diagnosis: schizophrenia, chronic ‐ no further details. N=30. Age: mean ˜ 32 years (SD ˜ 9), all >21. Sex: 17 M, 13 F. Exclusion: pregnant women, ill health, substance abuse. History: inpatients, hospitalisation duration <2 weeks‐>2 years.
Interventions	1. Loxapine: dose mean 44 mg/day, range 30‐90 mg/day. N=15. 2. Chlorpromazine: dose mean 453 mg/day, range 300‐900 mg/day. N=15. Antiparkinsonian drugs as required.
Outcomes	Global effect: CGI. Leaving the study early. Adverse effects. Unable to use ‐ Efficacy: (analyses of covariance ‐ no usable data). Mental state: BPRS (no usable data). Behaviour: NOSIE (no usable data). Adverse effects: Use of antiparkinsonian drugs (no usable data). Physiological measures: BP, ECG. pulse, ophthalmic tests, temperature, weight (no data). Laboratory tests: (no data).
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment (selection bias)	Unclear risk	B ‐ Unclear